Announcements

Lymphoma Patient Survey – Experience with pralatrexate (Folotyn) or belinostat (Beleodaq) for PTCL

If you have or had Peripheral T-Cell Lymphoma (PTCL) and have been treated with pralatrexate (Fotolyn) or belinostat (Beleodaq), you can help by completing our survey.

Lymphoma Canada is preparing a submission for the pan¬Canadian Oncology Drug Review (pCODR). The survey provides us with the patient input required for the submission. pCODR uses this information to help them make recommendations to provinces and territories regarding funding for new cancer drugs.

You do not need to live in Canada to complete this survey.

BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.

The survey will be open until midnight Pacific Time on Sunday, June 10, and should only take 10 minutes of your time.

You may access the survey by clicking the link below.

Peripheral T-Cell Lymphoma Patient Survey – Experience with Folotyn or Beleodaq

Please share and help us spread the word.

Thank you for your support.

 The above research study announcement posted on Cancer Survivors Network is intended to be informational in nature. The American Cancer Society does not warrant or guarantee the accuracy of the information provided and will not oversee or otherwise be involved in the conduct of the actual research study.  We recommend that you consult with your health care provider if you have concerns about your health before participating in any research study.  Any information you obtain through CSN announcements should not be used as a substitute for consultation with your health care provider

Want to help researchers understand why people choose, or decline, to participate in cancer clinical studies? Click the link below to learn more.

https://goo.gl/forms/1iHsLp2RFuRT3SVR2

Participants will be entered to win a $50 Amazon gift card. By being a part of this study, you will help researchers identify reasons people may or may not participate in clinical studies. With a better understanding of those reasons, researchers may be able to improve the clinical study process and experience for future patients, such as yourself.

The above research study announcement posted on Cancer Survivors Network is intended to be informational in nature. The American Cancer Society does not warrant or guarantee the accuracy of the information provided and will not oversee or otherwise be involved in the conduct of the actual research study.  We recommend that you consult with your health care provider if you have concerns about your health before participating in any research study.  Any information you obtain through CSN announcements should not be used as a substitute for consultation with your health care provider

If you’ve taken on caregiving for a loved one in recent years and face the challenges of balancing the healthcare needs of your loved one with your own needs, we want to hear your views.

The role of the caregiver, particularly in medical decision-making, is a role taken on urgently, without warning – and often with little expertise.  Yet the needs, challenges and issues that we face as we voluntarily care for loved ones with chronic and/or debilitating illnesses or conditions can be overwhelming and time-consuming.

Our hope is that your insights will help lead to better support for caregivers in this important role. More than 70 organizations are partnering on this survey because of their keen interest in helping you, the caregiver, as you navigate medical and care decisions that affect you and your loved one.

Findings from the survey will be published, shared widely through our partners’ networks and posted on the Rx4good website. If you have questions about the survey, please contact us at info@rx4good.com.

The above research study announcement posted on Cancer Survivors Network is intended to be informational in nature. The American Cancer Society does not warrant or guarantee the accuracy of the information provided and will not oversee or otherwise be involved in the conduct of the actual research study.  We recommend that you consult with your health care provider if you have concerns about your health before participating in any research study.  Any information you obtain through CSN announcements should not be used as a substitute for consultation with your health care provider.

My name of MJ DeCoteau and I am the executive director of Rethink Breast Cancer (www.rethinkbreastcancer.com) – a Canadian patient group dedicated to building community for young women dealing with breast cancer and providing support and resources to help them live the best quality of life.


We are looking for woman with HER2-positive early breast cancer and women who have been treated with Herceptin-Perjeta (pertuzumab-trastuzumab) combination therapy to talk about their treatment experience. We welcome feedback from women in the United States and other countries.


The Canadian government will soon be reviewing the use of Herceptin-Perjeta to treat HER2-positive early breast cancer that is node-positive or hormone receptor-negative, and Rethink Breast Cancer will be making a submission to ensure that patient voices are represented and considered during the review process.


If you are interested in talking about your experiences, we would like to ask you to complete this survey: https://www.surveymonkey.com/r/R76HZXY


If you would like to speak with us directly about your cancer or treatment experience, you can contact Shawna Rich-Ginsberg at shawna@rethinkbreastcancer.com.


We would also like to invite your family or friends to talk about their experience caring for a patient being treated with ribociclib: https://www.surveymonkey.com/r/RD79RF3


MJ DeCoteau

Founder + Executive Director

Rethink Breast Cancer

The above announcement posted on Cancer Survivors Network is intended to be informational in nature. The American Cancer Society does not warrant or guarantee the accuracy of the information provided and will not oversee or otherwise be involved in the conduct of the actual research study.  We recommend that you consult with your health care provider if you have concerns about your health before participating in any research study.  Any information you obtain through CSN announcements should not be used as a substitute for consultation with your health care provider.